As the world comes alive each spring, columnist Marisa Zeppieri must retreat to avoid a flare-up of her lupus ...

Telitacicept, a B-cell-targeting therapy developed by RemeGen, outperformed a placebo at reducing the severity of systemic lupus erythematosus (SLE) in a Phase 3 clinical trial in China, the company ...

Three new Phase 3 clinical trials testing the experimental therapy ianalumab in people with systemic lupus erythematosus (SLE) and lupus nephritis are now recruiting patients. All three trials are ...

Immpact Bio has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) for its ongoing Phase 1b/2 study evaluating the safety and efficacy of IMPT-514 in people ...

Brepocitinib, an investigational oral therapy, failed to show any benefits beyond a placebo in a Phase 2 clinical trial that tested it in adults with moderate to severely active systemic lupus ...

Scientist Akiko Iwasaki will receive the Dr. William E. Paul Distinguished Innovator Award (DIA) to investigate whether ancient viral DNA in our cells is a potential trigger for lupus. The $1 million ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google Living with lupus is such an individual, personal experience, ...

The U.S. Food and Drug Administration (FDA) has cleared Century Therapeutics to start a Phase 1 clinical trial that will test its off-the-shelf cell therapy CNTY-101 in people with systemic lupus ...

The U.S. Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab) as an add-on treatment for adults with lupus nephritis, a form of lupus marked by kidney damage. Lupus is an autoimmune ...

When the protein TLR7, or toll-like receptor 7 — which normally triggers an immune response against viruses and bacteria — instead builds up in immune cells, the immune system may turn against its own ...

Ventus Therapeutics plans to develop a new treatment candidate for lupus and other inflammatory diseases marked by the activation of the type 1 interferon immune system pathway, the company recently ...

A Phase 2 clinical trial testing Galápagos‘ experimental oral therapy GLPG3667 in people with systemic lupus erythematosus (SLE) has failed to meet its main goal, although some promising trends were ...